Cargando…

A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report

We report a case of a 68-year-old man diagnosed with pulmonary pleomorphic carcinoma who showed partial response after a single treatment with camrelizumab (PD1 monoclonal antibody). The patient’s tumor was positive for programmed cell death ligand 1 (PD-L1) and progressed rapidly after a course of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yi, Zhang, Hao, Shi, Junfeng, Wang, Tongshan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721275/ https://www.ncbi.nlm.nih.gov/pubmed/33299330 http://dx.doi.org/10.2147/OTT.S279004

Ejemplares similares

Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
por: Chang, Hao‐Chun, et al.
Publicado: (2020)

Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review
por: Shen, Tian, et al.
Publicado: (2020)

Camrelizumab monotherapy leading to partial remission for relapsed upper tract urothelial carcinoma after radical nephroureterectomy: a case report
por: Ni, Kangxin, et al.
Publicado: (2021)

Pulmonary pleomorphic carcinoma treated with PD‐1 inhibitor: Two case reports
por: Jiang, Tao, et al.
Publicado: (2023)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Camrelizumab—targeting a novel PD-1 epitope to treat hepatocellular carcinoma
por: Rakké, Yannick Sebastiaan, et al.
Publicado: (2020)

Efficacy and Safety of Camrelizumab Monotherapy and Combination Therapy for Cancers: A Systematic Review and Meta-Analysis
por: Wang, Jiting, et al.
Publicado: (2021)

Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer
por: Huang, Yahan, et al.
Publicado: (2022)

The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies
por: Wang, Xuan, et al.
Publicado: (2020)

Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab
por: Senoo, Satoru, et al.
Publicado: (2018)

Significant response of pulmonary sarcomatoid carcinoma with obstructive atelectasis to treatment with the PD-1 inhibitor camrelizumab combined with transbronchial cryoablation: A case report and literature review
por: Nian, Jiayun, et al.
Publicado: (2022)

Pulmonary pleomorphic carcinoma with few PD‐1‐positive immune cells and regulatory T cells that showed a complete response to nivolumab
por: Okamura, Kazuaki, et al.
Publicado: (2017)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
por: Li, Qi, et al.
Publicado: (2022)

Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study
por: Wei, Fuqun, et al.
Publicado: (2021)

Comprehensive molecular profiling of pulmonary pleomorphic carcinoma
por: Nagano, Masaaki, et al.
Publicado: (2021)

Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab
por: Ye, Wenling, et al.
Publicado: (2023)

Primary Pleural Squamous Cell Carcinoma, Highly Positive PD-L1, Shows Marked Response to Camrelizumab: A Case Report
por: Wang, Yao, et al.
Publicado: (2021)

A Case of Pulmonary Pleomorphic Carcinoma With Renal Metastasis()
por: Shimizu, Yasuomi, et al.
Publicado: (2014)

Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
por: Guo, Yusheng, et al.
Publicado: (2022)

Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy
por: Ohkuma, Ryotaro, et al.
Publicado: (2023)

Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: A case report
por: Kim, Tae‐Hun, et al.
Publicado: (2021)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
por: Faiena, Izak, et al.
Publicado: (2018)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
por: Ren, Yanqiao, et al.
Publicado: (2022)

Tumor-related gene expression levels in pulmonary pleomorphic carcinoma
por: Oyaizu, Takeshi, et al.
Publicado: (2015)

Effective combined therapy with ramucirumab for advanced pulmonary pleomorphic carcinoma
por: Nishioka, Naoya, et al.
Publicado: (2018)

Breast metastasis of pulmonary pleomorphic carcinoma: a case report
por: Fujita, Tomoyuki, et al.
Publicado: (2017)

Pulmonary pleomorphic carcinoma: A case report and review of the literature
por: Zhang, Xiangwei, et al.
Publicado: (2017)

Duodenal Metastasis of Pulmonary Pleomorphic Carcinoma: A Case Report
por: Matsuda, Masayuki, et al.
Publicado: (2021)

A case of pulmonary pleomorphic carcinoma associated with cystic airspace
por: Iwamura, Mamiko, et al.
Publicado: (2023)

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
por: Bu, Melissa T., et al.
Publicado: (2022)

Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pleomorphic Lobular Breast Carcinoma
por: Göker, Menekse, et al.
Publicado: (2023)

Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression
por: Ren, Yanqiao, et al.
Publicado: (2022)

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
por: Tan, Shuguang, et al.
Publicado: (2016)

Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient
por: Wang, Li, et al.
Publicado: (2022)

Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors
por: Mizugaki, Hidenori, et al.
Publicado: (2016)

Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
por: Falchook, Gerald S., et al.
Publicado: (2016)

Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials
por: Wei, Xiao-Li, et al.
Publicado: (2022)

Single pembrolizumab treatment causing profound durable response in a patient with pulmonary pleomorphic carcinoma
por: Tokuyasu, Hirokazu, et al.
Publicado: (2019)

Long‐term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report
por: Yorozuya, Takafumi, et al.
Publicado: (2020)

Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience
por: Liu, Qingyan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pg8d2r3ogv38v3vnnht7mffm42